" class="no-js "lang="en-US"> Marina Manuel Breysse - Medtech Alert
Saturday, September 13, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Manuel Marina Breysse

Marina Manuel Breysse

About Marina Manuel Breysse

Cardiologist specialized in arrhythmias and sports cardiology and IDOVEN’s CEO & CoFounder. He is a researcher at the National Centre for Cardiovascular Research (CNIC) and a doctor for the Spanish Agency for Health Protection in Sport (AEPSAD) of the Higher Sports Council (CSD).

Related Story

Artificial Intelligence

 Idoven Raises $19.8 Million in Funding to Redefine Detection and Precision Medicine of Cardiovascular Diseases with AI | Pharmtech Focus

Idoven Raises $19.8 Million in Funding to Redefine Detection and Precision Medicine of Cardiovascular Diseases with AI

June 22 2022

Idoven, a pioneering health tech company advancing early detection and precision medicine of cardiovascular disease, […]